Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, recently received Phase 1/2a IND approval from the U.S FDA on May 6th for its Glioblastoma Multiforme (GBM) treatment called RZ-001 and thus has achieved an important milestone for the company and the RNA editing field. RZ-001 initially obtained the IND approval with the indication for HCC, but Rznomics also found the great pre-clinical efficacy in GBM models and submitted the IND for...